Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Becton, Dickinson and Company    BDX

BECTON, DICKINSON AND COMPANY

(BDX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Becton Dickinson and : BD to Spend $1.2 Billion Upgrading Manufacturing Capacity for Prefillable Syringes

12/02/2020 | 07:30am EST

By Dave Sebastian

Becton, Dickinson & Co. said Wednesday it plans to spend about $1.2 billion expanding its manufacturing capacity for prefillable syringes and advanced drug delivery systems over the next four years.

The company said it will upgrade the capacity at six global locations and add a new Europe manufacturing facility, which it expects to start operating by the end of 2023.

"This investment positions BD to have the needed surge capacity for increased prefillable syringe demand during times of pandemic response or periods of significant growth of new injectable drugs and vaccines," said Eric Borin, worldwide president of BD Pharmaceutical Systems.

Six manufacturing facilities will get a portion of the investment include those in Columbus, Neb.; Cuautitlan, Mexico; Fukushima, Japan; Le Pont-de-Claix, France; Swindon, U.K.; and Tatabanya, Hungary.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

12-02-20 0729ET

Stocks mentioned in the article
ChangeLast1st jan.
BECTON, DICKINSON AND COMPANY 1.54% 261.74 Delayed Quote.4.60%
TOKYO ELECTRIC POWER COMPANY HOLDINGS, INCORPORATED -0.92% 323 End-of-day quote.18.75%
All news about BECTON, DICKINSON AND COMPANY
01/15BECTON DICKINSON AND : S&P Revises Becton Dickinson Outlook to Stable From Negat..
MT
01/14BECTON DICKINSON AND : BD Advances Immunology Research by Enabling Researchers t..
AQ
01/13BECTON DICKINSON AND : UBS Adjusts Price Target on Becton Dickinson and Co. to $..
MT
01/12Lands' End, Luminex rise; Boston Scientific, Carnival fall
AQ
01/12BECTON DICKINSON AND : BD Announces First-Ever Peer-Reviewed Study to Evaluate S..
AQ
01/12SECTOR UPDATE : Health Care Stocks Mixed Premarket Tuesday
MT
01/12BECTON DICKINSON AND : Guides Fiscal Q1 Revenue Above Street View
MT
01/12BECTON DICKINSON & CO : Results of Operations and Financial Condition (form 8-K)
AQ
01/12BECTON DICKINSON AND : Sees Strong 1Q Revenue, Boosts 2021 Guidance
DJ
01/12BECTON DICKINSON AND : BD Provides Updates To Its Fiscal 2021 Financial Outlook ..
PR
More news
Financials (USD)
Sales 2021 19 163 M - -
Net income 2021 2 680 M - -
Net Debt 2021 11 866 M - -
P/E ratio 2021 27,9x
Yield 2021 1,40%
Capitalization 76 127 M 76 127 M -
EV / Sales 2021 4,59x
EV / Sales 2022 4,42x
Nbr of Employees 72 000
Free-Float 79,1%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 277,19 $
Last Close Price 261,74 $
Spread / Highest target 14,6%
Spread / Average Target 5,90%
Spread / Lowest Target -1,81%
EPS Revisions
Managers and Directors
NameTitle
Thomas E. Polen President, Chief Executive Officer & Director
Vincent A. Forlenza Executive Chairman
Christopher R. Reidy EVP, Chief Financial & Administrative Officer
John A. DeFord Chief Technology Officer & Executive VP
William R. Sigmund Chief Medical Officer & EVP
Sector and Competitors
1st jan.Capitalization (M$)
BECTON, DICKINSON AND COMPANY4.60%76 127
ABBOTT LABORATORIES1.65%190 701
MEDTRONIC PLC-0.28%157 229
HOYA CORPORATION-2.24%50 041
ALIGN TECHNOLOGY, INC.6.15%44 726
BAXTER INTERNATIONAL INC.-0.25%40 886